Biocept Inc (NASDAQ:BIOC) Shares Were Downgraded Today by Westpark Capital

May 24, 2018 - By Harriett Tippett

Biocept Inc (NASDAQ:BIOC) Receives a Downgrade

In an analyst report sent to clients and investors on Wednesday morning, Westpark Capital decreased their rating for shares of Biocept Inc (NASDAQ:BIOC) to a Hold.

The stock decreased 1.27% or $0.0023 during the last trading session, reaching $0.1802. About 393,193 shares traded. Biocept, Inc. (NASDAQ:BIOC) has declined 85.25% since May 24, 2017 and is downtrending. It has underperformed by 96.80% the S&P500.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $12.29 million. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer.

More news for Biocept, Inc. (NASDAQ:BIOC) were recently published by: Seekingalpha.com, which released: “Biocept’s (BIOC) CEO Michael Nall on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. Streetinsider.com‘s article titled: “WestPark Capital Downgrades Biocept (BIOC) to Neutral” and published on May 23, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: